An interventional study of low FODMAP diet and Lactose Sachet in Inflammatory Bowel Diseases, sponsored by McMaster University. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by McMaster University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies in Inflammatory Bowel Diseases with a site in Canada — 35 open to participants now, 50 under way, 6 of them phase 3. Inflammatory Bowel Diseases · Canada.
Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, this one is the 88th largest by enrollment of the 119 interventional ones that give a count, is one of 13 that started in 2024, is one of 46 with no phase, reaches primary completion later than 17 of the 49 other live ones, and was the 132nd registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →35 of the 156 studies in Inflammatory Bowel Diseases with a site in Canada are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Canada, United States, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in Canada, United States, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of British Columbia · Sites in Canada
Ages 9–17
University of British Columbia · Sites in Canada
Ages 19+ · Women only · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 28 · Phase 4 10
First in 2002; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 120 across the 119 interventional studies, 157 across the 36 observational. Of the 91 that completed or were terminated, 32 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 156 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 9 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Inflammatory Bowel Diseases with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07814274University of British ColumbiaProspective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development | 2027-02-01 |
| NCT05722236Jennifer JonesIBD Strong Peer2Peer for Self-Management of Psychological Distress | 2027-03 |
| NCT06548399McMaster UniversityLongitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease | 2027-03-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Prospective single-blinded intervention feasibility study is the utilization of the AIRE-2 device and FoodMarble app to elucidate the interplay among diet, symptoms, and microbial fermentable features in IBD patients with persistent intestinal symptoms and non-IBD controls.
AIRE-2 captures exhaled hydrogen and methane and FoodMarble app records breath levels, symptoms and dietary intake.
The main questions it aims to answer are:
You will:
Study Design Type:
Prospective single-blinded intervention feasibility study
Methodology/Study Design:
A cohort of IBD patients and non-IBD controls will be recruited for this study. You will be instructed to use a handheld breathalyzer device, AIRE-2, to measure exhaled H2 and CH4 gas production, and its smartphone app, FoodMarble, will be used to log your diet and symptoms for a period of 5 weeks, as follows:
AIRE-2 will be used before and after two meals each day - the first meal and the last meal of the day. You will breathe into the AIRE-2 device before eating to obtain the baseline value. After the meal, you will breathe into the AIRE-2 60 minutes postprandially. The exhaled H2 and CH4 measurements will be automatically logged into the FoodMarble app, which is connected via Bluetooth. You will log your food intake and symptoms in FoodMarble. Symptoms scores will be recorded at the same time that the AIRE- 2 device is being used - 60 minutes postprandial. You will be asked not to drink alcohol during the meals that will be recorded, as this will skew the device results. You will be informed that you can consume alcoholic drinks after doing the postprandial breath test.
Study procedure:
The criteria were revised on the registry on Nov 17, 2026. See what changed
Inclusion criteria (IBD):
Exclusion criteria (IBD):
A total of 30 adult IBD patients (18-75 years old), 15 ulcerative colitis (UC) and 15 Crohn's disease (CD) patients, will be recruited at the Digestive Diseases Clinic, McMaster University, Hamilton, Ontario.
Controls: A total of 30 non-IBD volunteers from the same household as the recruited IBD patients or the general population who do not have any IBS-like symptoms will be recruited as controls.
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with IBD, under clinical remission since more than 3 months, having at least one symptom
Dietary Supplement: low FODMAP diet · Dietary Supplement: Lactose Sachet · Dietary Supplement: Fructose Sachet · Dietary Supplement: Sorbitol Sachet · Dietary Supplement: Inulin Sachet · Device: AIRE-2 Portable breath analyzer
Non-IBD controls recruited from the household or general population, with no history of IBD or active gastrointestinal disease.
Dietary Supplement: low FODMAP diet · Dietary Supplement: Lactose Sachet · Dietary Supplement: Fructose Sachet · Dietary Supplement: Sorbitol Sachet · Dietary Supplement: Inulin Sachet · Device: AIRE-2 Portable breath analyzer
You consume low FODMAP diet for 24 hours before taking the FODMAP challenge
You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you will consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. 25g sachet having lactose roughly equal to amount of lactose present in 1 large glass of milk
You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. 25g sachet having fructose roughly equal to the amount of fructose present in 2 large apples
You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. 10g sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune
You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. A 10g sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic
The AIRE-2 breath analyzer will capture hydrogen and methane at baseline and after every fodmap challenge
Proof of data collection/Adherence to the protocol
For each data set, we will divide the number of logged data divided by the total data expected to be logged. For example, the number of breath tests using AIRE-2 logged by the participant / total expected. This will also apply to the diet log. The results will be expressed in %.
Time frame: 40 months
Comparison of positive breath between IBD and non-IBD controls
average of # \>3 breath test score / total group #
Time frame: 40 months
Prevalence of positive score with symptoms between IBD and non-IBD controls
\# of events when \>3 breath test score match with symptomatic event / total positive test events
Time frame: 40 months
Correlation of positive breath tests with severity of symptoms
using person correlation coefficient
Time frame: 40 months
Correlation of breath scores with food reported as being intolerant by the participants
matching between reported dietary triggers at baseline and positive breath test
Time frame: 40 months
Microbiome taxa
We will explore the associations between fecal microbiome taxa and exhaled H₂ and CH₄ levels. The microbiome profile will be characterized using shotgun metagenomic sequencing of fecal samples.
Time frame: 40 months
Relative abundance of microbial metabolic pathways
Microbial metabolic pathways and functional profiles will be characterized using shotgun metagenomic sequencing and correlated with dietary intake, exhaled H₂ and CH₄ levels, and symptom patterns.
Time frame: 40 months
Ran from Aug 2024 to primary completion in Nov 2026, 26 months.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 26 months is close to that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Nov 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.